Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older
Oren Auster, Uriah Finkel, Noa Dagan, Noam Barda, Alon Laufer, Ran D. Balicer, Shay Ben‐Shachar
Abstract
This survey study assesses the occurrence of short-term adverse events in adults 60 years or older who received a booster dose of the BNT162B2 mRNA vaccine.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakMedicineAdverse effectTerm (time)VirologyMEDLINEPharmacologyInternal medicineBiologyOutbreakPhysicsInfectious disease (medical specialty)BiochemistryDiseaseQuantum mechanicsSARS-CoV-2 and COVID-19 ResearchHeparin-Induced Thrombocytopenia and ThrombosisViral Infections and Immunology Research